Recombinant anti-human-IL-1 beta Antibody (Canakinumab)
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at support@abeomics.com
Target: IL-1 Beta
Generic name: Canakinumab
Product Origin: Recombinant in CHO cells
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass with a molecular mass of 145157 Daltons when deglycosylated. Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra).
References:
1. Church LD, McDermott MF: Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009 Feb;11(1):81-89.
2. Lachmann HJ, et al.: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009 Jun 4;360(23):2416-25. doi:10.1056/NEJMoa0810787
| Purification : | Purity: >98.0% as determined by SEC-HPLC & SDS-PAGE. |
| Content : | 10mM Phosphate pH-7.0, 150 mM NaCl, 20% Glycerol |
| Storage condition : | Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles. |
| Amino acid sequence : | PepMap Analysis of N terminal amino acids sequence : H chain: QVQLVESGGG, L chain: EIVLTQSPDFQS |
Specificity: Human IL1 beta. Does not cross react with other members of the interleukin-1 family.
Inquire for more than 1 mg quantities.
Availability 5-7 weeks.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|
There are currently no product reviews
|
